

Supplementary Table 1. Pooled relative risks (RRs) and 95% confidence intervals (CIs) for combined *GSTM1*, *GSTT1*, or *NAT2* genotype and regular genital talc use history and ovarian cancer risk in the New England Case-Control Study (NECC) and the Nurses' Health Study (NHS)*†

| | Total epithelial ovarian cancer | | | Serous invasive ovarian cancer | | |
|---|---------------------------------|----------------|------------------------|--------------------------------|----------------|------------------------|
| | No regular talc | Regular talc | <i>P</i> -interaction‡ | No regular talc | Regular talc | <i>P</i> -interaction‡ |
| <i>GSTM1</i> | | | | | | |
| <i>GSTM1</i> present (+) | 1.0 (ref.) | 1.6 (1.2, 2.1) | | 1.0 (ref.) | 2.0 (1.5, 2.8) | |
| Cases/controls | 480/646 | 189/165 | | 173/546 | 90/135 | |
| <i>GSTM1</i> null (-) | 1.0 (0.8, 1.1) | 1.2 (0.9, 1.5) | 0.13 | 1.1 (0.8, 1.3) | 1.4 (1.0, 2.0) | 0.05 |
| Cases/controls | 498/690 | 179/198 | | 190/566 | 76/165 | |
| <i>GSTT1</i> | | | | | | |
| <i>GSTT1</i> present (+) | 1.0 (ref.) | 1.2 (1.0, 1.5) | | 1.0 (ref.) | 1.5 (1.2, 2.0) | |
| Cases/controls | 785/1035 | 278/301 | | 288/867 | 129/247 | |
| <i>GSTT1</i> null (-) | 0.9 (0.7, 1.1) | 1.7 (1.2, 2.4) | 0.03 | 0.9 (0.6, 1.2) | 1.9 (1.2, 2.9) | 0.17 |
| Cases/controls | 194/300 | 87/67 | | 71/246 | 38/57 | |
| <i>NAT2</i> | | | | | | |
| <i>NAT2</i> rapid/intermediate acetylator | 1.0 (ref.) | 1.5 (1.1, 2.1) | | 1.0 (ref.) | 1.9 (1.2, 2.8) | |
| Cases/controls | 330/459 | 128/113 | | 123/393 | 57/92 | |
| <i>NAT2</i> slow acetylator | 0.9 (0.6, 1.2) | 1.1 (0.6, 1.9) | 0.60 | 0.9 (0.7, 1.2) | 1.4 (1.0, 2.0) | 0.57 |
| Cases/controls | 552/819 | 217/233 | | 204/661 | 96/192 | |
| <i>GSTM1</i> / <i>GSTT1</i> genotype | | | | | | |
| <i>GSTM1</i> +, <i>GSTT1</i> + | 1.0 (ref.) | 1.4 (1.0, 1.9) | | 1.0 (ref.) | 1.8 (1.2, 2.6) | |
| Cases/controls | 378/479 | 142/140 | | 136/406 | 68/112 | |
| <i>GSTM1</i> -, <i>GSTT1</i> + | 0.9 (0.8, 1.1) | 1.0 (0.8, 1.4) | | 1.0 (0.8, 1.3) | 1.3 (0.9, 1.9) | |
| Cases/controls | 400/541 | 135/154 | | 151/454 | 60/131 | |
| <i>GSTM1</i> +, <i>GSTT1</i> - | 0.8 (0.6, 1.1) | 2.6 (1.1, 6.1) | | 0.8 (0.5, 1.2) | 2.7 (1.4, 5.2) | |
| Cases/controls | 98/158 | 47/24 | | 34/135 | 22/23 | |
| <i>GSTM1</i> -, <i>GSTT1</i> - | 0.8 (0.5, 1.2) | 1.2 (0.7, 2.2) | 0.03 | 0.9 (0.6, 1.5) | 1.4 (0.7, 2.6) | 0.10 |
| Cases/controls | 94/138 | 40/41 | | 36/108 | 16/33 | |

*Unconditional (NECC) and conditional (NHS) logistic regression adjusted for age, study center (NECC only), duration of oral contraceptive use (months), parity (continuous), tubal ligation, body mass index (kg/m², continuous), and duration of postmenopausal hormone use (months)

†*P*-values for tests for heterogeneity comparing the NECC and NHS results were all >0.22, except the *p*-values for the *NAT2* slow acetylator genotype and risk of total ovarian cancer, which were >0.08

‡*P*-values for interaction based on likelihood ratio test comparing unconditional logistic regression models with and without gene-talc interaction terms